Remove Big Data Remove Clinical Development Remove Nurses
article thumbnail

BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with DeliriumFifth potential indication for BXCL501, an orally dissolving thin film

The Pharma Data

The Richmond Agitation–Sedation Scale was developed in a collaborative effort with practitioners representing critical care physicians, nurses, and pharmacists and its validation and reliability is well documented.

Trials 40